Search research articles
Contact Us
Filters
Showing results (431-440 of 478) with videos related to
Page
of 48
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group
L Del Mastro, M Venturini, R Lionetto, et al.
Clinical and Experimental Immunology
|
July 11, 2000
T cell receptor repertoire and function in patients with DiGeorge syndrome and velocardiofacial syndrome
M Pierdominici, M Marziali, A Giovannetti, et al.
Clinical Chemistry
|
June 28, 2001
Biomarkers of bone turnover after a short period of steroid therapy in elderly men
F Paglia, S Dionisi, S De Geronimo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
J A Oshaughnessy, J Blum, V Moiseyenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2001
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
M Venturini, A Michelotti, P Papaldo, et al.
American Journal of Nephrology
|
March 2, 2011
Sirolimus prevents short-term renal changes induced by ischemia-reperfusion injury in rats
C Esposito, F Grosjean, M Torreggiani, et al.
Emerging Infectious Diseases
|
October 5, 2001
West Nile encephalitis in Israel, 1999: the New York connection
M Giladi, E Metzkor-Cotter, D A Martin, et al.
Cancer
|
December 18, 2001
Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma
A Ardizzoni, M A Cafferata, M Paganuzzi, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer
M Venturini, L Del Mastro, F Testore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 1995
Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer
A F Sobrero, C Aschele, A P Guglielmi, et al.
Page
of 48
Search research articles
Search
Showing results (431-440 of 478) with videos related to
Sort By:
Page
of 48
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group
L Del Mastro, M Venturini, R Lionetto, et al.
Clinical and Experimental Immunology
|
July 11, 2000
T cell receptor repertoire and function in patients with DiGeorge syndrome and velocardiofacial syndrome
M Pierdominici, M Marziali, A Giovannetti, et al.
Clinical Chemistry
|
June 28, 2001
Biomarkers of bone turnover after a short period of steroid therapy in elderly men
F Paglia, S Dionisi, S De Geronimo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
J A Oshaughnessy, J Blum, V Moiseyenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2001
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
M Venturini, A Michelotti, P Papaldo, et al.
American Journal of Nephrology
|
March 2, 2011
Sirolimus prevents short-term renal changes induced by ischemia-reperfusion injury in rats
C Esposito, F Grosjean, M Torreggiani, et al.
Emerging Infectious Diseases
|
October 5, 2001
West Nile encephalitis in Israel, 1999: the New York connection
M Giladi, E Metzkor-Cotter, D A Martin, et al.
Cancer
|
December 18, 2001
Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma
A Ardizzoni, M A Cafferata, M Paganuzzi, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1996
Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer
M Venturini, L Del Mastro, F Testore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 1995
Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer
A F Sobrero, C Aschele, A P Guglielmi, et al.
Page
of 48